Symbols / OTLK
OTLK Chart
About
Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration agreements with Cencora. Outlook Therapeutics, Inc. was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 30.21M |
| Enterprise Value | 62.36M | Income | -102.86M | Sales | 205.70K |
| Book/sh | -0.60 | Cash/sh | 0.10 | Dividend Yield | — |
| Payout | 0.00% | Employees | 17 | IPO | — |
| P/E | — | Forward P/E | -0.99 | PEG | — |
| P/S | 146.87 | P/B | -0.69 | P/C | — |
| EV/EBITDA | -1.06 | EV/Sales | 303.14 | Quick Ratio | 0.18 |
| Current Ratio | 0.35 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -2.89 | EPS next Y | -0.42 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-05-14 | ROA | -209.04% |
| ROE | — | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 11.16% | Profit Margin | 0.00% | Shs Outstand | 73.51M |
| Shs Float | 67.73M | Short Float | 6.19% | Short Ratio | 0.39 |
| Short Interest | — | 52W High | 3.39 | 52W Low | 0.38 |
| Beta | -0.07 | Avg Volume | 5.96M | Volume | 667.71K |
| Target Price | $5.38 | Recom | Buy | Prev Close | $0.40 |
| Price | $0.41 | Change | 2.75% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$5.38
Mean price target
2. Current target
$0.41
Latest analyst target
3. DCF / Fair value
$-8.43
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.41
Low
$0.50
High
$10.00
Mean
$5.38
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-18 | reit | HC Wainwright & Co. | Neutral → Neutral | $1 |
| 2026-02-18 | main | Chardan Capital | Neutral → Neutral | $1 |
| 2026-01-05 | main | Chardan Capital | Neutral → Neutral | $1 |
| 2026-01-02 | main | HC Wainwright & Co. | Neutral → Neutral | $1 |
| 2025-12-22 | main | Ascendiant Capital | Buy → Buy | $10 |
| 2025-09-30 | reit | HC Wainwright & Co. | Neutral → Neutral | $1 |
| 2025-09-22 | main | Ascendiant Capital | Buy → Buy | $8 |
| 2025-08-29 | down | Guggenheim | Buy → Neutral | — |
| 2025-08-29 | down | HC Wainwright & Co. | Buy → Neutral | $1 |
| 2025-08-28 | main | Chardan Capital | Neutral → Neutral | $3 |
| 2025-08-15 | main | Chardan Capital | Neutral → Neutral | $3 |
| 2025-06-06 | main | Ascendiant Capital | Buy → Buy | $21 |
| 2025-02-24 | main | Ascendiant Capital | Buy → Buy | $24 |
| 2025-02-18 | main | HC Wainwright & Co. | Buy → Buy | $3 |
| 2025-02-18 | main | Chardan Capital | Neutral → Neutral | $3 |
| 2025-01-17 | reit | Guggenheim | Buy → Buy | $12 |
| 2025-01-17 | reit | HC Wainwright & Co. | Buy → Buy | $30 |
| 2024-12-02 | down | Chardan Capital | Buy → Neutral | — |
| 2024-11-29 | main | BTIG | Buy → Buy | $9 |
| 2024-11-29 | reit | HC Wainwright & Co. | Buy → Buy | $30 |
- Fresenius Medical Care Shares Drop After Outlook Underwhelms - WSJ ue, 24 Feb 2026 12
- Retina treatment LYTENAVA lines up Swiss launch in 2027 with Mediconsult - Stock Titan hu, 19 Feb 2026 14
- Goldman raises Q4 oil price outlook on lower OECD stocks - Reuters Mon, 23 Feb 2026 07
- Outlook Therapeutics Shares Sink After FDA Issues Another CRL On Wet AMD Therapy - Nasdaq hu, 01 Jan 2026 08
- Retail investors among Outlook Therapeutics, Inc.'s (NASDAQ:OTLK) largest shareholders, saw gain in holdings value after stock jumped 14% last week - simplywall.st hu, 18 Dec 2025 08
- Outlook Therapeutics stock plunges after FDA rejects wet AMD drug application - Investing.com Wed, 31 Dec 2025 08
- OTLK Stock Crashes 67% in a Week: Here's What You Need to Know - Yahoo Finance Wed, 07 Jan 2026 08
- New Analyst Forecast: $OTLK Given $0.5 Price Target | OTLK Stock News - Quiver Quantitative Wed, 18 Feb 2026 12
- February 2026 US Stock Market Outlook: Where We See Investing Opportunities | Morningstar Nordics - Morningstar Canada ue, 10 Feb 2026 08
- 2026 outlook: Economic upside, stock market downside - corporate.vanguard.com Wed, 10 Dec 2025 08
- OTLK Stock Crashes 54% as FDA Issues Second CRL for Eye Disease Drug - Zacks Investment Research Fri, 29 Aug 2025 07
- FDA Rejects Corcept and Outlook Filings, Crushing Stock Prices - BioSpace Fri, 02 Jan 2026 08
- Palo Alto Networks' Deals Are Dragging on Its Profit Outlook. The Stock Is Falling - Investopedia Wed, 18 Feb 2026 17
- Eye drug firm Outlook Therapeutics expands in Europe, seeks FDA talks - Stock Titan ue, 17 Feb 2026 13
- US FDA declines to approve Outlook's eye disease drug for second time in 2025 - Reuters Wed, 31 Dec 2025 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 4285714 | 6000000 | — | Stock Award(Grant) at price 1.40 per share. | SUKHTIAN GHIATH M | Director and Beneficial Owner of more than 10% of a Class of Security | — | 2025-05-27 00:00:00 | I |
| 1 | 3458571 | 7712613 | — | Conversion of Exercise of derivative security at price 2.23 per share. | SUKHTIAN GHIATH M | Director and Beneficial Owner of more than 10% of a Class of Security | — | 2025-01-17 00:00:00 | I |
| 2 | 3458571 | 8681013 | — | Conversion of Exercise of derivative security at price 2.51 per share. | SUKHTIAN GHIATH M | Director and Beneficial Owner of more than 10% of a Class of Security | — | 2025-01-17 00:00:00 | I |
| 3 | 5000 | 28446 | — | Purchase at price 5.69 per share. | KENYON LAWRENCE A. | Chief Financial Officer | — | 2024-09-26 00:00:00 | D |
| 4 | 714286 | 6157145 | — | Purchase at price 8.62 per share. | SYNTONE VENTURES, L.L.C. | Beneficial Owner of more than 10% of a Class of Security | — | 2024-04-15 00:00:00 | D |
| 5 | 1881 | 22242 | — | Purchase at price 11.82 per share. | HADDADIN YEZAN MUNTHER | Director | — | 2024-03-28 00:00:00 | D |
| 6 | 2305714 | — | — | Stock Award(Grant) at price 0.00 per share. | SUKHTIAN GHIATH M | Director and Beneficial Owner of more than 10% of a Class of Security | — | 2024-03-18 00:00:00 | I |
| 7 | 62484 | 26243 | — | Purchase at price 0.42 per share. | EVANSON JEFF | Officer | — | 2024-03-07 00:00:00 | D |
Financials
| Line Item | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 1.03M | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.02 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -106.59M | -110.73M | -55.88M | -63.80M |
| TotalUnusualItems | 43.02M | 38.64M | -526.74K | -559.62K |
| TotalUnusualItemsExcludingGoodwill | 43.02M | 38.64M | -526.74K | -559.62K |
| NetIncomeFromContinuingOperationNetMinorityInterest | -62.42M | -75.37M | -58.98M | -66.05M |
| ReconciledDepreciation | 117.05K | 113.86K | 44.19K | 204.69K |
| ReconciledCostOfRevenue | 1.36M | 0.00 | ||
| EBITDA | -63.58M | -72.09M | -56.40M | -64.36M |
| EBIT | -63.69M | -72.21M | -56.45M | -64.56M |
| NetInterestIncome | -193.39K | -2.25M | -1.56M | -1.49M |
| InterestExpense | 283.13K | 3.16M | 2.53M | 1.49M |
| InterestIncome | 89.74K | 906.15K | 971.48K | |
| NormalizedIncome | -104.41M | -114.00M | -58.46M | -65.49M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -62.42M | -75.37M | -58.98M | -66.05M |
| TotalExpenses | 68.48M | 71.70M | 53.13M | 63.07M |
| TotalOperatingIncomeAsReported | -67.06M | -71.70M | -53.13M | -63.07M |
| DilutedAverageShares | 34.80M | 18.55M | 12.51M | 10.60M |
| BasicAverageShares | 34.80M | 18.55M | 12.51M | 10.60M |
| DilutedEPS | -1.79 | -4.06 | -4.80 | -6.20 |
| BasicEPS | -1.79 | -4.06 | -4.80 | -6.20 |
| DilutedNIAvailtoComStockholders | -62.42M | -75.37M | -58.98M | -66.05M |
| NetIncomeCommonStockholders | -62.42M | -75.37M | -58.98M | -66.05M |
| OtherunderPreferredStockDividend | 0.00 | |||
| NetIncome | -62.42M | -75.37M | -58.98M | -66.05M |
| NetIncomeIncludingNoncontrollingInterests | -62.42M | -75.37M | -58.98M | -66.05M |
| NetIncomeContinuousOperations | -62.42M | -75.37M | -58.98M | -66.05M |
| TaxProvision | -1.55M | 2.80K | 2.80K | 2.80K |
| PretaxIncome | -63.98M | -75.36M | -58.98M | -66.05M |
| OtherIncomeExpense | 3.28M | -1.41M | -4.29M | -1.49M |
| OtherNonOperatingIncomeExpenses | -39.60M | -39.95M | -3.76M | -882.90K |
| SpecialIncomeCharges | 0.00 | -577.66K | -1.03M | 0.00 |
| OtherSpecialCharges | 577.66K | 1.03M | ||
| ImpairmentOfCapitalAssets | 0.00 | |||
| EarningsFromEquityInterest | -141.01K | -100.74K | -11.00K | -48.73K |
| GainOnSaleOfSecurity | 43.02M | 38.64M | 50.92K | 465.78K |
| NetNonOperatingInterestIncomeExpense | -193.39K | -2.25M | -1.56M | -1.49M |
| InterestExpenseNonOperating | 283.13K | 3.16M | 2.53M | 1.49M |
| InterestIncomeNonOperating | 89.74K | 906.15K | 971.48K | |
| OperatingIncome | -67.06M | -71.70M | -53.13M | -63.07M |
| OperatingExpense | 67.12M | 71.70M | 53.13M | 63.07M |
| ResearchAndDevelopment | 27.18M | 41.76M | 26.45M | 42.33M |
| SellingGeneralAndAdministration | 39.94M | 29.94M | 26.67M | 20.74M |
| GeneralAndAdministrativeExpense | 39.94M | 29.94M | 26.67M | 20.74M |
| OtherGandA | 23.28M | 19.05M | 17.75M | 11.62M |
| SalariesAndWages | 16.66M | 10.89M | 8.93M | 9.12M |
| GrossProfit | 57.20K | 0.00 | ||
| CostOfRevenue | 1.36M | 0.00 | ||
| TotalRevenue | 1.41M | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 1.41M | 0.00 | 0.00 | 0.00 |
| Line Item | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 |
|---|---|---|---|---|
| OrdinarySharesNumber | 53.89M | 23.91M | 13.01M | 11.37M |
| ShareIssued | 53.89M | 23.91M | 13.01M | 11.37M |
| NetDebt | 21.86M | 14.51M | 12.16M | |
| TotalDebt | 30.19M | 29.74M | 35.56M | 10.96M |
| TangibleBookValue | -32.19M | -73.08M | -14.44M | 8.74M |
| InvestedCapital | -2.24M | -43.64M | 21.11M | 19.65M |
| WorkingCapital | -28.43M | -15.14M | -15.75M | 7.79M |
| NetTangibleAssets | -32.19M | -73.08M | -14.44M | 8.74M |
| CapitalLeaseObligations | 247.70K | 297.83K | 4.27K | 43.01K |
| CommonStockEquity | -32.19M | -73.08M | -14.44M | 8.74M |
| TotalCapitalization | -32.19M | -73.08M | -14.44M | 8.74M |
| TotalEquityGrossMinorityInterest | -32.19M | -73.08M | -14.44M | 8.74M |
| StockholdersEquity | -32.19M | -73.08M | -14.44M | 8.74M |
| RetainedEarnings | -605.71M | -543.28M | -467.92M | -408.94M |
| AdditionalPaidInCapital | 572.98M | 469.97M | 453.35M | 415.40M |
| CapitalStock | 538.87K | 239.06K | 130.13K | 2.27M |
| CommonStock | 538.87K | 239.06K | 130.13K | 2.27M |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 50.77M | 101.90M | 46.74M | 19.79M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 4.96M | 59.35M | 6.22K | 61.41K |
| DerivativeProductLiabilities | 4.77M | 59.10M | 6.22K | 57.14K |
| LongTermDebtAndCapitalLeaseObligation | 188.80K | 246.92K | 0.00 | 4.27K |
| LongTermCapitalLeaseObligation | 188.80K | 246.92K | 0.00 | 4.27K |
| LongTermDebt | 10.89M | |||
| CurrentLiabilities | 45.81M | 42.55M | 46.73M | 19.73M |
| CurrentDebtAndCapitalLeaseObligation | 30.01M | 29.49M | 35.56M | 10.95M |
| CurrentCapitalLeaseObligation | 58.90K | 50.91K | 4.27K | 38.75K |
| CurrentDebt | 29.95M | 29.44M | 35.55M | 10.92M |
| OtherCurrentBorrowings | 29.95M | 29.44M | 35.55M | 10.92M |
| CurrentNotesPayable | 0.00 | |||
| PensionandOtherPostRetirementBenefitPlansCurrent | 3.03M | 1.01M | 919.97K | 1.98M |
| PayablesAndAccruedExpenses | 12.78M | 12.05M | 10.26M | 6.80M |
| CurrentAccruedExpenses | 2.29M | 2.22M | 1.83M | 1.45M |
| InterestPayable | 0.00 | 12.91K | ||
| Payables | 10.49M | 9.83M | 8.43M | 5.35M |
| TotalTaxPayable | 302.00K | 1.86M | 1.86M | 1.86M |
| IncomeTaxPayable | 302.00K | 1.86M | 1.86M | 1.86M |
| AccountsPayable | 10.19M | 7.97M | 6.57M | 3.49M |
| TotalAssets | 18.58M | 28.82M | 32.30M | 28.53M |
| TotalNonCurrentAssets | 1.20M | 1.41M | 1.32M | 1.01M |
| OtherNonCurrentAssets | 417.52K | 439.28K | 501.30K | 132.01K |
| InvestmentsAndAdvances | 552.18K | 693.19K | 793.93K | 804.93K |
| LongTermEquityInvestment | 552.18K | 693.19K | 793.93K | 804.93K |
| InvestmentsinJointVenturesatCost | 552.18K | 693.19K | 793.93K | 804.93K |
| InvestmentsInOtherVenturesUnderEquityMethod | 853.66K | |||
| NetPPE | 225.51K | 274.64K | 26.17K | 70.36K |
| AccumulatedDepreciation | -1.07M | -903.73K | ||
| GrossPPE | 225.51K | 274.64K | 26.17K | 70.36K |
| OtherProperties | 225.51K | 274.64K | 26.17K | 70.36K |
| CurrentAssets | 17.39M | 27.42M | 30.98M | 27.52M |
| OtherCurrentAssets | 4.48M | 12.49M | 7.59M | 10.12M |
| PrepaidAssets | 10.12M | 7.03M | ||
| Inventory | 3.34M | 0.00 | ||
| FinishedGoods | 29.63K | |||
| WorkInProcess | 958.54K | |||
| RawMaterials | 2.35M | |||
| Receivables | 1.49M | 0.00 | ||
| AccountsReceivable | 1.49M | 0.00 | ||
| CashCashEquivalentsAndShortTermInvestments | 8.08M | 14.93M | 23.39M | 17.40M |
| CashAndCashEquivalents | 8.08M | 14.93M | 23.39M | 17.40M |
| Line Item | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 |
|---|---|---|---|---|
| FreeCashFlow | -51.83M | -68.79M | -42.97M | -56.67M |
| RepaymentOfDebt | -36.14M | -4.27K | -10.23M | -12.32M |
| IssuanceOfDebt | 33.10M | 0.00 | 30.00M | 10.00M |
| IssuanceOfCapitalStock | 25.40M | 60.33M | 30.02M | 62.31M |
| InterestPaidSupplementalData | 0.00 | 475.00K | 1.16M | 1.56M |
| EndCashPosition | 8.08M | 14.93M | 23.39M | 17.40M |
| BeginningCashPosition | 14.93M | 23.39M | 17.40M | 14.48M |
| ChangesInCash | -6.84M | -8.46M | 6.00M | 2.92M |
| FinancingCashFlow | 44.98M | 60.33M | 48.97M | 59.59M |
| CashFlowFromContinuingFinancingActivities | 44.98M | 60.33M | 48.97M | 59.59M |
| NetOtherFinancingCharges | -823.89K | -600.00K | -8.03K | |
| ProceedsFromStockOptionExercised | 22.63M | 0.00 | 0.00 | 205.85K |
| NetCommonStockIssuance | 25.40M | 60.33M | 30.02M | 62.31M |
| CommonStockIssuance | 25.40M | 60.33M | 30.02M | 62.31M |
| NetIssuancePaymentsOfDebt | -3.04M | -4.27K | 19.77M | -2.32M |
| NetLongTermDebtIssuance | -3.04M | -4.27K | 19.77M | -2.32M |
| LongTermDebtPayments | -36.14M | -4.27K | -10.23M | -12.32M |
| LongTermDebtIssuance | 33.10M | 0.00 | 30.00M | 10.00M |
| InvestingCashFlow | 0.00 | |||
| CashFlowFromContinuingInvestingActivities | 0.00 | |||
| NetBusinessPurchaseAndSale | 0.00 | |||
| PurchaseOfBusiness | 0.00 | |||
| OperatingCashFlow | -51.83M | -68.79M | -42.97M | -56.67M |
| CashFlowFromContinuingOperatingActivities | -51.83M | -68.79M | -42.97M | -56.67M |
| ChangeInWorkingCapital | 4.86M | -3.02M | 4.75M | -1.68M |
| ChangeInOtherCurrentLiabilities | -50.13K | 3.41K | -27.00K | -42.85K |
| ChangeInOtherCurrentAssets | -95.25K | -5.90K | -208.20K | 0.00 |
| ChangeInPayablesAndAccruedExpense | 1.82M | 1.89M | 2.37M | 1.45M |
| ChangeInAccruedExpense | 1.71M | 491.73K | -711.66K | 156.14K |
| ChangeInPayable | 111.42K | 1.39M | 3.08M | 1.30M |
| ChangeInAccountPayable | 1.67M | 1.39M | 3.08M | 1.30M |
| ChangeInTaxPayable | -1.55M | 0.00 | 0.00 | |
| ChangeInIncomeTaxPayable | -1.55M | 0.00 | 0.00 | |
| ChangeInPrepaidAssets | 8.01M | -4.90M | 2.62M | -3.09M |
| ChangeInInventory | -3.34M | 0.00 | ||
| ChangeInReceivables | -1.49M | 0.00 | ||
| ChangesInAccountReceivables | -1.49M | 0.00 | ||
| OtherNonCashItems | 33.52M | 2.68M | 1.37M | 1.66M |
| StockBasedCompensation | 8.90M | 5.39M | 5.55M | 7.71M |
| UnrealizedGainLossOnInvestmentSecurities | 6.07M | 2.46M | 3.76M | 882.90K |
| AssetImpairmentCharge | 0.00 | |||
| DepreciationAmortizationDepletion | 117.05K | 113.86K | 44.19K | 204.69K |
| DepreciationAndAmortization | 117.05K | 113.86K | 44.19K | 204.69K |
| OperatingGainsLosses | -42.87M | -1.05M | 537.74K | 608.35K |
| EarningsLossesFromEquityInvestments | 141.01K | 100.74K | 11.00K | 48.73K |
| GainLossOnInvestmentSecurities | -43.02M | -1.15M | -50.92K | -465.78K |
| NetIncomeFromContinuingOperations | -62.42M | -75.37M | -58.98M | -66.05M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for OTLK
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|